Nature: One inoculation provides near-complete protection, and the results of the Johnson and Johnson's new crown vaccine animal experiment sharply.

Guide: A single dose of vaccine induces a powerful neutralizing antibody response, and after 6 weeks of vaccination, almost all rhesus monkeys are immune to the virus. As
of 6:30 a.m. Beijing time on July 31, the cumulative number of confirmed cases of new coronary pneumonia (COVID-19) worldwide exceeded 17.43 million, and the cumulative number of deaths reached 670,000, and the epidemic continued to develop.
, the U.S. company Moderna, Pfizer inc. and Germany's BioNTech have all published the results of trials of the COVID-19 vaccine.
now, Johnson and Johnson has brought the latest research results from its new crown vaccine, and the competition for new-crown vaccine development has intensified.
July 30, local time, the top journal Nature released in an accelerated preview of the results of Johnson and Johnson's new coronavirus (SARS-CoV-2) vaccine in non-human primates based on the Ad26 adenovirus vector.
studies have shown that a single dose of vaccine induces a powerful neutralizing antibody response, and after 6 weeks of vaccination, almost all rhesus monkeys are immune to the virus.

in the study, researchers created seven Ad26 vectors that express the SARS-CoV-2 sting protein (S) mutation.
then vaccinated 52 rhesus monkeys with different designs and evaluated the vaccine-induced neutralizing antibody response using fake and live viruses.
results showed that the Ad26-S.PP vaccine induced the highest pseudoviral and live virus NAb titer (median of 408 and 113, respectively), and the median NAb dyslethey of rhesus monkeys recovered from the vaccine was 4 times higher than that of previously reported rhesus monkeys and human patients, and their bronchial alcoave irrigation (BAL) was able to detect induced antidosis of antidote systirate protein-specific G g and IgA antibody reactions.
immune response in the vaccinated rhesus monkeys six weeks after vaccination, the researchers let the virus attack the nasal cavity and trachea of the rhesus monkeys, and found that the strains had very few clinical symptoms after being attacked by the virus.
no virus was detected in the Rhesus MONKEY BAL, where the Ad26-S.PP vaccine was given, compared to all rhesus monkeys in the control group, and only a small amount of the virus was detected in the nasal swab (NS), indicating that the Ad26-S.PP vaccine provided near-complete protection in both the lower and upper respiratory tracts.
the limitation of the study on viral load of rhesus monkeyBAL and NS after the SARS-CoV-2 attack was that the persistence of nAb responses caused by these vaccines was not assessed.
However, the Ad26-S.PP vaccine caused AT-cell reactions in Th1 bias rather than Th2 bias, and inoculated animals did not exhibit increased viral replication or clinical disease.
in addition, the immune phenotype of the BAL cell subgroup showed an increase in eosinophils in rhesus monkeys after vaccination compared to the control group. "Our SARS-CoV-2 vaccine has generated a strong antibody response, protected from a single dose," Paul Stoffels, chief scientific officer at
Johnson and Johnson, said in a statement.
this result gives us confidence as we move forward with vaccine development and increase production.
" is understood to have launched human trials in Belgium and the United States in late July, and plans to launch phase 3 clinical trials in September.
References: S1 Single-shot Ad26 vaccine srs rst SARS-CoV-2 in rhesus macaques. The results of the new crown vaccine animal trial of the Johnson and Johnson single dose are good and the final phase of the trial is scheduled to be launched in September.